These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37609458)

  • 21. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Gamma-Aminobutyric Acid B Receptor in Depression and Reward.
    Jacobson LH; Vlachou S; Slattery DA; Li X; Cryan JF
    Biol Psychiatry; 2018 Jun; 83(11):963-976. PubMed ID: 29759132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Precision Psychiatry: Biomarker-Guided Tailored Therapy for Effective Treatment and Prevention in Major Depression.
    Jones C; Nemeroff CB
    Adv Exp Med Biol; 2021; 1305():535-563. PubMed ID: 33834417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach.
    Magaraggia I; Kuiperes Z; Schreiber R
    Neurobiol Learn Mem; 2021 Sep; 183():107467. PubMed ID: 34048913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The neural correlates of anhedonia in major depressive disorder.
    Keedwell PA; Andrew C; Williams SC; Brammer MJ; Phillips ML
    Biol Psychiatry; 2005 Dec; 58(11):843-53. PubMed ID: 16043128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
    Hjalmarsson L; Corcos M; Jeammet P
    Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.
    Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J
    Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial.
    Costi S; Morris LS; Kirkwood KA; Hoch M; Corniquel M; Vo-Le B; Iqbal T; Chadha N; Pizzagalli DA; Whitton A; Bevilacqua L; Jha MK; Ursu S; Swann AC; Collins KA; Salas R; Bagiella E; Parides MK; Stern ER; Iosifescu DV; Han MH; Mathew SJ; Murrough JW
    Am J Psychiatry; 2021 May; 178(5):437-446. PubMed ID: 33653118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel antidepressant drugs: Beyond monoamine targets.
    Gonda X; Dome P; Neill JC; Tarazi FI
    CNS Spectr; 2023 Feb; 28(1):6-15. PubMed ID: 34588093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A precision medicine-based, 'fast-fail' approach for psychiatry.
    Williams LM; Hack LM
    Nat Med; 2020 May; 26(5):653-654. PubMed ID: 32405056
    [No Abstract]   [Full Text] [Related]  

  • 31. Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress.
    Rincón-Cortés M; Grace AA
    Behav Brain Res; 2020 Feb; 379():112367. PubMed ID: 31739001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders.
    Kozlowska U; Nichols C; Wiatr K; Figiel M
    J Neurochem; 2022 Jul; 162(1):89-108. PubMed ID: 34519052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report.
    Allen TA; Lam RW; Milev R; Rizvi SJ; Frey BN; MacQueen GM; Müller DJ; Uher R; Kennedy SH; Quilty LC
    Psychol Med; 2019 Jul; 49(10):1629-1638. PubMed ID: 30220263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting opioid dysregulation in depression for the development of novel therapeutics.
    Browne CA; Lucki I
    Pharmacol Ther; 2019 Sep; 201():51-76. PubMed ID: 31051197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs.
    Dale E; Bang-Andersen B; Sánchez C
    Biochem Pharmacol; 2015 May; 95(2):81-97. PubMed ID: 25813654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of Neuroimaging-Based Biomarkers in Major Depression.
    Han KM; Ham BJ; Kim YK
    Adv Exp Med Biol; 2021; 1305():85-99. PubMed ID: 33834396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nitrous Oxide: an emerging novel treatment for treatment-resistant depression.
    Quach DF; de Leon VC; Conway CR
    J Neurol Sci; 2022 Mar; 434():120092. PubMed ID: 34953347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electroconvulsive therapy effects on anhedonia and reward circuitry anatomy: A dimensional structural neuroimaging approach.
    Cano M; Lee E; Worthley A; Ellard K; Barbour T; Soriano-Mas C; Camprodon JA
    J Affect Disord; 2022 Sep; 313():243-250. PubMed ID: 35764228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deep phenotyping towards precision psychiatry of first-episode depression - the Brain Drugs-Depression cohort.
    Jensen KHR; Dam VH; Ganz M; Fisher PM; Ip CT; Sankar A; Marstrand-Joergensen MR; Ozenne B; Osler M; Penninx BWJH; Pinborg LH; Frokjaer VG; Knudsen GM; Jørgensen MB
    BMC Psychiatry; 2023 Mar; 23(1):151. PubMed ID: 36894940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transdiagnostic biomarker approaches to mental health disorders: Consideration of symptom complexity, comorbidity and context.
    McQuaid RJ
    Brain Behav Immun Health; 2021 Oct; 16():100303. PubMed ID: 34589795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.